REDWOOD CITY, Calif., April 1, 2026 /PRNewswire/ — Synthego, a pioneering leader in genome engineering solutions, today announced that the Supreme Court of the United States has denied a petition for a writ of certiorari from Agilent Technologies, Inc., effectively concluding a multi-year legal challenge and solidifying the invalidation of two Agilent CRISPR-related patents that claimed a widely used and previously known technology.

The Supreme Court’s decision leaves intact the June 2025 ruling by the U.S. Court of Appeals for the Federal Circuit, which affirmed an earlier Patent Trial and Appeal Board (PTAB) decision that all claims of Agilent’s U.S. Patent Nos. 10,337,001 and 10,900,034 were unpatentable. These patents were directed to specific chemical modifications of guide RNAs (gRNAs) used in CRISPR-Cas gene editing.

“We are deeply grateful for this final resolution,” said Craig Christianson, CEO at Synthego. “Our goal in pursuing this challenge was never about a single dispute, but about our commitment to the broader scientific community. By helping to clear the patent thicket surrounding fundamental gene-editing modifications, we hope to ensure that researchers and therapeutic developers can continue to innovate without the burden of invalid patent claims.”

The conclusion of this case comes at a pivotal time for Synthego as it continues to expand its leadership in the cell and gene therapy (CGT) space and is driving new offerings supporting molecular biology and diagnostic development. The company’s focus on providing high-quality, accessible tools for genomic medicine is exemplified by its recent advancements in novel nucleases, including its high-fidelity hfCas12Max and eSpOT-ON proprietary enzymes.

“This result aligns perfectly with our mission to accelerate the path from discovery to cure,” continued Christianson. “As we introduce our own novel nucleases and CRISPR technologies, we are inspired by the opportunity to contribute to a more open and navigable intellectual property landscape. We believe this clarity benefits the entire industry and, most importantly, the patients who await life-changing therapies.”

With the chain of appeals now exhausted, the invalidation of these patents removes a significant barrier to the use of essential gRNA modifications, fostering an environment where innovation in CRISPR-enabled research and therapeutics can flourish.

About Synthego

Synthego is a pioneering biotechnology company specializing in synthetic biology and genome engineering. Dedicated to providing scientists with the tools, expertise, and support needed to accelerate scientific discovery, Synthego’s expansion into molecular and clinical diagnostic reagents reaffirms its commitment to innovation and leadership in the life sciences industry.

Website: www.synthego.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/synthego-welcomes-supreme-court-order-finalizing-invalidation-of-agilent-crispr-patents-302731924.html